President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
The stock market is shrinking for several key reasons, but there's a way for investors to maneuver it, says Citi Research strategist Robert Buckland.Trading Nationread more
The Supreme Court refused to overturn a precedent that strengthened the power of government regulators in a closely watched case that could have had broad ramifications for...Politicsread more
Apple made Comcast and Charter agree to sell iPads, Apple TVs and other lower-volume devices as part of the cable companies' deal to offer the iPhone on their mobile service.Technologyread more
President Trump says "I hope we don't" have a war with Iran but it "would not last very long."Politicsread more
Stocks rose on Wednesday as comments from Treasury Secretary Steven Mnuchin lifted expectations of a potential trade deal between China and the U.S.Marketsread more
Presidents Donald Trump and Xi Jinping are scheduled to meet Saturday, the second day of the two-day G-20 summit in Osaka, Japan.Politicsread more
Gene therapy stocks are a huge opportunity for growth-oriented investors, according to Goldman Sachs.
The firm is optimistic about this new innovative area of biotechnology, where scientists create disease treatments by editing or replacing human genes.
"We believe investors underappreciate the potential for genome medicine to not only address rare diseases with no existing or limited treatments but also the much larger markets for common diseases," analyst Salveen Richter wrote in a note to clients entitled "The Genome Revolution" Tuesday. "We continue to see upside for the best positioned companies based on the combination of catalysts, rising TAMs [total addressable markets] and M&A potential."
Richter estimates the market size for gene therapies could be as large as $4.8 trillion as "genes are the foundations of all biological activity."
Here are three buy-rated stocks recommended by Goldman Sachs, along with the firm's current price targets.